The FDA has hit the green light for Xofigo--initially called Alpharadin or radium-223 chloride--for castration-resistant prostate cancer. The approval demonstrates the agency's growing comfort with targeted cancer therapies that arrive at its doorstep with compelling overall survival benefits. The approval comes just three months after the FDA granted priority review status to the radiopharmaceutical therapy, from Bayer and Norway's Algeta. Report